🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New supplement! 📗 Major advances in the systemic treatment of #NSCLC have been made over the past 20 years. CANCER is pleased to deliver 8 comprehensive reviews on targeted therapies for NSCLC written by leading global experts. acsjournals.onlinelibrary.wiley.com/toc/10970142/2… OncoAlert

Evolution of HER2 testing over 40 yrs. IHC lacks the dynamic range to predict outcomes with T-DXd, yet novel quantitative assays are emerging. We presented data with HS-HER2 to predict T-DXd activity at #ESMO24. More data coming at #ASCO25. Stay tuned. nature.com/articles/s4157…

🚨 New Perspective on ctDNA in NSCLC: Understanding Acquired Resistance 🧬🩸 📖 NatureRevClinOncol , 2025 🔬 This expert review outlines how circulating tumor DNA (ctDNA) is reshaping the detection of acquired resistance to targeted therapies in metastatic NSCLC. 🔍 Key

A friendly reminder of what a real astronaut looks like. NASA's Suni Williams. 🇸🇮🇺🇸🚀

🫁 Stage III NSCLC 🫁 🫁 ASCO Guideline Rapid Recommendation Update Clinical Insights

Vegemite is back on the menu in Canada. Thanks to Prime Minister @markjcarney for working with Australia to make it happen. 🇦🇺🇨🇦

🎉 Mark Your Calendars! The 7th Annual ISLB Congress is coming to Orlando, Florida 🇺🇸 | Nov 1–3, 2025 🧬🩸 Join scientists, clinicians, and innovators from around the world to shape the future of liquid biopsy. Expect: ✅ Groundbreaking science ✅ Networking with global leaders

📗 From the Targeted Therapies in NSCLC supplement | A review discussing ALK-positive lung cancer, including treatment efficacy, safety profiles, mechanisms of resistance, and promising new treatments in the field. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… OncoAlert Dr. Nadia Ghazali IASLC

Have you started your application to join us this summer as we launch our next crew to the International Space Station? Tell us why you should attend the #Crew11 #NASASocial—Monday, April 28 is your deadline: nasa.gov/social-media/n…

Heading to #ASCO25 for the first time as a trainee? It can be overwhelming but also incredibly rewarding! Here’s some honest advice I wish I’d had as a resident/fellow. 👇 What are YOUR top tips for first-timers? Share & RT!

🚨 #ASCO25 Update 🚨 🧬 Sacituzumab govitecan (SG) + pembrolizumab vs 💉 Chemo + pembro in 1L PD-L1+ mTNBC 📊 ASCENT-04 / KEYNOTE-D19 results: 🕒 PFS: 11.2 vs 7.8 mo 📉 HR: 0.65 (95% CI: 0.51–0.84), P = .0009 🎯 ORR: 59.7% vs 53.2% ⏳ DOR: 16.5 vs 9.2 mo 📉 Discontinuation due to

Phase 3 oncology RCTs often report positive results based on alternative end points, but actual improvements in overall survival or quality of life are rare, highlighting need to prioritize these outcomes in future research & regulatory processes. #ASCO25 ja.ma/3FCoVHI

🔥🚨OncoAlert Hot Off The Press Just published NEJM in conjunction with presentation ASCO #ASCO25 Results of #DeLLphi304 phase trial of: #Tarlatamab vs #Chemotherapy in 2nd Tx for advanced #SmallCell #LungCancer ✅#mOS: 13.6 vs 8.3 months (HR: 0.6) ✅More Improvement in

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

Original Article: Structured Exercise after Adjuvant Chemotherapy for Colon Cancer (CHALLENGE phase 3 trial) nej.md/4mh5RPL #ASCO25 | ASCO

🔥🚨OncoAlert Hot Off The Press Just published The Lancet In conjunction with presentation ASCO #ASCO25 ✅Results of #IMforte trial of: #Lurbinectedin + #Atezolizumab as 1st line #Maintenance Tx in #Patients with #ExtensiveStage #SmallCell #LungCancer. 👇🏻

ASCO redeemed itself when you watch orals & the trials presented are positive for OS. Again and again the most important endpoint for any oncology clinical trial is overall survival. Better studies should have been presented in the plenary that actually have an OS benefit

Our review on key advancements in #liquidbiopsy in 2024 is finally out! This work was made possible thanks to the incredible team effort of the International Society of Liquid Biopsy Young Committee. 📰Check it out! ➡️ sciencedirect.com/science/articl…

International Society of Liquid Biopsy Carolina Reduzzi Mohamed A Gouda Cristofanilli CTC Laboratory Eleonora Nicolò Letizia Pontolillo @shurbisinghal @diegodemiguelperez Erick Saldanha, MD Pasquale Pisapia Konstantinos Venetis Ana Ortega Franco Dr. Nadia Ghazali Christian Rolfo Umberto Malapelle M JOSE SERRANO Lab (LB&Cancer Interception group) David Gandara ELO

Great paper from our ISLB Young Committee! A huge effort to keep sharing #LiquidBiopsy knowledge through reviews and editorials after major conferences worldwide. Follow us for more LB updates and insights! 🌍🧬 #ISLB #sciencecommunication